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Background-—Mechanisms underlying iron homeostasis dysregulation in patients with chronic heart failure remain unsettled. In
cardiomyocyte models, norepinephrine may lead to intracellular iron depletion, but the potential association between
catecholamines (sympathetic activation markers) and iron metabolism biomarkers in chronic heart failure is unknown.
Methods and Results-—In this cross-sectional analysis, we studied the association between plasma norepinephrine levels and
serum iron status biomarkers indicating iron storage (ferritin), iron transport (transferrin saturation), and iron demand (soluble
transferrin receptor) in a prospective cohort of 742 chronic heart failure patients (mean age, 7211 years; 56% male). Impaired
iron status was defined as ferritin <100 lg/L or transferrin saturation <20%. Impaired iron status was observed in 69% of patients.
In multivariate models, greater norepinephrine levels were associated with impaired iron transport (transferrin saturation <20%,
odds ratio=2.28; 95% CI [1.19–4.35]; P=0.013), but not with impaired iron storage (ferritin <100 lg/L, odds ratio=1.25; 95% CI
[0.73–2.16]; P=0.415). Norepinephrine was a significant predictor of increased iron demand (soluble transferrin receptor,
standardized b-coefficient=0.12; P=0.006) and low transferrin saturation (standardized b-coefficient=0.12; P=0.003). However,
norepinephrine levels were not associated with iron or ferritin levels (P>0.05). Adjusted norepinephrine marginal means were
significantly higher in patients with impaired iron status compared with those with normal iron status (528 pg/mL [505–551]
versus 482 pg/mL [448–518], respectively; P=0.038).
Conclusions-—In chronic heart failure patients, increased sympathetic activation estimated with norepinephrine levels is
associated with impaired iron status and, particularly, dysregulation of biomarkers suggesting impaired iron transport and
increased iron demand. Whether the relationship between norepinephrine and iron metabolism is bidirectional and entails causality
need to be elucidated in future research. ( J Am Heart Assoc. 2019;8:e010887. DOI: 10.1161/JAHA.118.010887.)
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I ron deficiency is associated with worse quality of life,functional capacity, and prognosis in patients with chronic
heart failure (CHF), regardless of the presence of anemia.1–6
Consequently, current guidelines recommend assessing the
iron profile of patients with CHF and treating them with
intravenous iron, when appropriate.7–10 Nevertheless, the
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ORIGINAL RESEARCH
mechanisms underlying dysregulation of iron homeostasis in
patients with CHF are still not well established.
Sympathetic activation, which entails increased serum
levels of norepinephrine, is one of the main therapeutic targets
in CHF because of its deleterious long-term effects,7,8,11–15
particularly in patients with reduced left ventricle ejection
fraction (LVEF). In this context, recent studies have shown that
in cardiomyocyte models, norepinephrine leads to intracellular
iron depletion.16 These results in cellular models suggest a role
of sympathetic activation in the development of iron home-
ostasis dysregulation. However, the association between
sympathetic activity and iron status has not been evaluated
so far at the patient level.
The aim of this study was thus to assess the potential
association between sympathetic activation, as measured
using plasma norepinephrine levels, and several biomarkers of
serum iron homeostasis, including ferritin as a maker of iron
availability, transferrin saturation (TSAT) as a marker of iron
supply, and the soluble transferrin receptor (sTfR) as a marker
of iron demand, in a large population of consecutive patients
with CHF followed in a specialized, multidisciplinary CHF unit,
in which all these measurements were available.
Methods
Data are available upon request from a third party. Because of
the sensitive nature of the data collected for this study,
reasonable requests to access the data set from qualified
researchers trained in human subject confidentiality protocols
may be sent to Bellvitge Biomedical Research Institute at the
corresponding author.
Study Design and Study Population
The DAMOCLES (Definition of the neuro-hormonal activation,
myocardial function, genomic expression and clinical out-
comes in heart failure patients) study was a single-center,
observational, prospective cohort study of 1236 consecutive
patients diagnosed with CHF. The methodology of the
DAMOCLES has been published previously by our group.2,17
Briefly, for inclusion, patients had to be diagnosed with CHF
according to the European Society of Cardiology diagnostic
criteria, had at least 1 recent acute decompensation of CHF
requiring intravenous diuretic therapy (either hospitalized or in
the day care hospital), and had to be in stable condition at the
time of study entry. Exclusion criteria were: significant
primary valvular disease, clinical signs of fluid overload,
pericardial disease, restrictive cardiomyopathy, hypertrophic
cardiomyopathy, hemoglobin levels <8.5 g/dL, active malig-
nancy, and chronic liver disease. The study was approved by
the local committee of ethics for clinical research and was
conducted in accord with the principles of the Declaration of
Helsinki. All patients gave written informed consent before
study entry.
For the present analysis, norepinephrine levels were
evaluated in all consecutive participants included in the
DAMOCLES study between June 2004 and January 2011.
Patients included in the DAMOCLES study after this period did
not have norepinephrine levels measured and thus were
excluded from this analysis.
Baseline Evaluation: Catecholamines, Iron
Parameters, and Other Laboratory Measurements
Methods of blood collection and management, as well as the
quantification of norepinephrine levels performed in the
baseline DAMOCLES study visit, have been previously
reported.17 In summary, patients were resting in a supine
position in a quiet room for 30 to 60 minutes after venous
cannulation. Tubes with blood samples were immersed in
melting ice and frozen until they were processed. Levels of
norepinephrine were measured from 1.5 mL of plasma by
high-resolution liquid chromatography. Norepinephrine analy-
sis had a coefficient of variation of 8.7%. Serum N-terminal
pro-b-type natriuretic peptide levels were measured in pg/mL
using an immunoassay based on chemiluminescence using
the Elecsys System (Roche, Indianapolis, IN). Serum iron (mg/
dL) was measured using spectrophotometry; serum ferritin
(ng/mL) and transferrin (mg/dL) were measured using
immunoturbidimetry. TSAT was estimated using the formula:
TSAT=serum iron (mg/dL)/[serum transferrin (mg/dL)
91.25]. Iron status was also assessed by measuring serum
soluble transferrin receptor (sTfR; in mg/L) levels using an
enzyme immunoassay. Hemoglobin (g/dL) was measured with
Clinical Perspective
What Is New?
• The exact mechanisms by which chronic heart failure
patients develop iron deficiency are still unknown.
• To the best of our knowledge, we demonstrate, for the first
time, an interplay between raised sympathetic nervous
system activity and systemic iron deficiency in patients with
chronic heart failure and, particularly, with those biomarkers
that suggest impaired iron transport (transferrin saturation
<20%) and increased iron demand (raised soluble transferrin
receptor levels).
What Are the Clinical Implications?
• Our results may support the hypothesis that iron deficiency
might not just be a comorbidity, but may also be a key
element in the pathophysiological sequence leading to, and
promoting the progression of, chronic heart failure.
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impedance laser colorimetry. Glomerular filtration rate was
estimated from serum creatinine using the formula of the
Modification of Diet in Renal Disease Study Group equation.18
Study Definitions
Impaired iron status was defined as ferritin <100 ng/mL or
TSAT <20%. To explore the association between nore-
pinephrine and different components of the iron pathway,
we also defined impaired iron storage as ferritin <100 ng/
mL and impaired iron transport as TSAT <20%. Increased
iron demand (high sTfR) was defined as levels of sTfR
>75th percentile of its distribution in the study population.
Anemia was defined using the World Health Organization
criteria (cut-off values of 13 g/dL in men and 12 g/dL in
women).19
Statistical Analyses
This was a cross-sectional analysis using the baseline data
from the DAMOCLES study. Demographic and clinical char-
acteristics and laboratory test results were summarized using
basic descriptive statistics, both in the overall cohort as well
as stratified by norepinephrine tertiles. For quantitative
variables, the arithmetic mean (and SD) or median (and
interquartile range) were reported as appropriate, and P
values were obtained using ANOVA and Kruskal–Wallis tests,
respectively. For qualitative variables, number and percent-
ages within specified groups were calculated, and P values
were derived using v2 tests.
When necessary, natural logarithm transformation was
used to fit skewed continuous variables into normal distribu-
tions. Specifically, norepinephrine was modeled in 2 ways for
the analyses: as a continuous exposure (log-transformed), as
well as a dichotomous exposure (“high norepinephrine” levels
defined as norepinephrine >90th percentile [1050 pg/mL] of
the distribution in the study population, as compared with
≤90th percentile).
To assess the association between sympathetic activation,
as measured using norepinephrine levels, and the different
iron status biomarkers, we first used logistic and linear
regression to assess the crude (unadjusted) associations
between norepinephrine and each of the relevant iron status
biomarkers. Also, generalized additive models were used to
graphically display the relationship between log nore-
pinephrine serum levels and log TSAT, log sTfR, and log
ferritin, respectively. Unadjusted logistic and linear regression
analyses were also used to assess the bivariate associations
between each of the predictors included in Table 1 and each
of the iron status biomarkers.
Multivariable-adjusted linear and logistic regression mod-
els were used to evaluate the adjusted associations between
higher levels of norepinephrine as an independent variable
and levels of each of the iron status biomarkers as the
dependent variables. Multivariable models used step-wise
forward conditional methods and were adjusted for the
predictors that showed a significant association with impaired
iron status in the bivariate logistic regression analyses.
Finally, general linear models were used to calculate
adjusted marginal means and 95% CIs of norepinephrine
according to different iron and anemia states. All general
linear models were adjusted for factors associated with
increased norepinephrine levels. Factors associated with
raised norepinephrine levels have been described previously
by our group.17
All statistical tests and CIs were constructed with a type 1
error alpha level of 5% with no adjustments for multiplicity,
and P<0.05 were considered statistically significant. SPSS
(version 22.0; IBM, Armonk, NY) and R software (version
3.0.1; R Foundation for Statistical Computing, Vienna, Austria)
were used for statistical analyses.
Results
Study Population
Of the 1236 CHF patients included in the DAMOCLES study,
494 did not have baseline levels of norepinephrine measured
and were excluded from the present analyses. This defined a
final study population of 742 patients. Serum iron status
parameters were available in all DAMOCLES study
participants.
Baseline Characteristics of the Study Participants
Baseline characteristics of the study participants, overall
and by norepinephrine tertiles, are shown in Table 1.
Overall, mean age was 72 years, and 56% participants were
male. Mean LVEF was 44%, median N-terminal pro-b-type
natriuretic peptide levels were 1547 pg/mL, and 45% of
patients had a New York Heart Association functional class
of III or IV. Median levels of norepinephrine were 523
(351–730), and 515 (69%) patients had impaired iron
status.
By norepinephrine tertiles, patients in the upper tertile of
norepinephrine (higher sympathetic activation) were older,
more frequently male, and had a worse CHF clinical profile,
with higher N-terminal pro-b-type natriuretic peptide levels,
lower body mass index, and worse New York Heart Association
functional class than their lower norepinephrine tertile coun-
terparts. Also, the higher the norepinephrine tertile, the higher
the prevalence of all iron abnormalities. Interestingly, LVEF,
systolic blood pressure, and heart rate did not differ between
categories of norepinephrine levels.
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Age, y 7211 6911 7311 7511 <0.001
Sex, male, n (%) 418 (56) 137 (55) 134 (54) 147 (60) 0.40
BMI, kg/m2 286 306 285 275 <0.001
Systolic BP, mm Hg 12523 12724 12424 12322 0.13
Heart rate, bpm 7415 7315 7515 7416 0.62
NT-proBNP, pg/mL 1547 [662–3942] 1124 [489–2460] 1672 [647–3495] 2391 [923–6436] <0.001
eGFR, mL/min per 1.73 m2 5924 6124 5923 5626 0.08
LVEF, % 4417 4517 4417 4318 0.46
HFpEF, n (%) 278 (38) 91 (37) 95 (38) 92 (37) 0.933
HFmrEF, n (%) 116 (16) 45 (18) 38 (15) 33 (13) 0.346
HFrEF, n (%) 348 (47) 112 (45) 115 (47) 121 (49) 0.655
Etiology of CHF, ischemic, n (%) 303 (41) 112 (45) 96 (39) 95 (39) 0.24
Atrial fibrillation, n (%) 234 (32) 72 (29) 85 (34) 77 (31) 0.45
NYHA class III or IV, n (%) 330 (45) 98 (40) 104 (42) 128 (52) 0.012
Norepinephrine, median (IQR) 523 [351–730] 313 [252–352] 524 [467–592] 858 [730–1111] <0.001
Comorbidities, n (%)
Hypertension 582 (78) 190 (77) 195 (79) 197 (80) 0.64
Diabetes mellitus 345 (47) 130 (52) 110 (44) 105 (43) 0.67
CKD (eGFR <60 mL/min/1.73 m2) 418 (56) 126 (51) 140 (57) 152 (62) 0.048
Anemia 365 (49) 124 (50) 115 (46) 126 (51) 0.53
COPD 163 (22) 57 (23) 49 (20) 57 (23) 0.59
Obesity 247 (33) 101 (41) 84 (34) 62 (25) 0.001
Impaired iron status 515 (69) 172 (69) 164 (66) 179 (73) 0.278
Impaired iron transport 438 (59) 137 (55) 139 (56) 162 (66) 0.028
Impaired iron storage 280 (38) 104 (42) 88 (36) 280 (38) 0.247
Treatments, n (%)
ACEI or ARBs 578 (78) 205 (83) 196 (79) 177 (72) 0.014
Beta-blockers 656 (88) 214 (86) 224 (90) 218 (89) 0.37
Aldosterone antagonists 308 (42) 110 (44) 101 (41) 97 (39) 0.52
Digoxine 96 (13) 34 (14) 38 (15) 24 (10) 0.166
Statins 426 (57) 147 (59) 139 (56) 140 (57) 0.754
Loop diuretics 655 (88) 219 (88) 222 (90) 214 (87) 0.684
Anticoagulants 356 (48) 107 (43) 118 (48) 131 (53) 0.079
ICD 22 (3) 11 (5) 2 (1) 9 (4) 0.046
CRT 10 (1) 4 (2) 4 (2) 2 (1) 0.68
Serum levels
Hemoglobin, g/dL 12.41.8 12.51.8 12.61.8 12.51.9 0.87
Ferritin, lg/L [IQR] 142 [73–272] 141 [75–262] 132 [71–251] 155 [70–289] 0.229*
TSAT, % 17.8 [12.2–24.5] 18.4 [12.8–25.5] 19.1 [13.1–25.2] 16.1 [11.2–23.3] <0.001*
Transferrin 24847 24341 24946 25151 0.116
Raised sTfR, n (%) 133 (25) 38 (24) 38 (20) 57 (30) 0.058*
Continued
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Norepinephrine and Serum Iron Status
Biomarkers
Figure 1 displays crude (unadjusted) associations between
norepinephrine levels (log transformed) and levels of each iron
deficiency biomarker. There was evidence of an inverse,
nonlinear association between higher norepinephrine levels
and lower TSAT (P value for linear component, 0.001; P value
for the nonlinear component, 0.046) and of a positive, linear
association between norepinephrine levels and sTfR (P value
for the linear component, 0.007). In contrast, there was no
evidence of a crude association between norepinephrine
levels and ferritin.
In univariate logistic regression analyses (Table 2), both a
log-unit increase in norepinephrine levels as well as a
norepinephrine level >90th percentile (as compared with
<90th percentile) was significantly associated with higher
odds of iron deficiency.
Other Factors Associated With Serum Iron Status
Biomarkers in Unadjusted Analyses
Table 2 presents the baseline variables that showed statis-
tically significant associations with abnormal iron status in
bivariate logistic regression analyses. Hyponatremia, anemia,
and norepinephrine levels were the strongest, statistically
significant clinical predictors.
Multivariable-Adjusted Associations Between
Norepinephrine and Serum Iron Status
Biomarkers
In line with the main objectives of the study, multivariable
logistic regression analyses adjusting for variables signifi-
cantly associated with iron deficiency were performed. High
levels of norepinephrine (defined as norepinephrine >90th
percentile of the distribution, as compared to norepinephrine
≤90th percentile) were significantly associated with impaired
iron status (odds ratio, 2.21; 95% CI, 1.11–4.41), impaired
iron transport (odds ratio, 2.28; 95% CI, 1.19–4.35), and
increased iron demand (odds ratio, 2.23; 95% CI, 1.24–4.01),
whereas it was not associated with impaired iron storage (low
ferritin alone) or with presence of anemia (Table 3). Interest-
ingly, the association between norepinephrine levels and the
different biomarkers suggesting iron deficiency was indepen-
dent of LVEF. We examined the interaction between LVEF
categories and this association, and it was not significant
(P=0.865).
To analyze the association between iron deficiency and
norepinephrine, which was the main objective of the study, we
performed bi- and multivariable-adjusted linear regression
analyses between increasing levels of log-transformed nore-
pinephrine and levels of several serum iron status biomarkers.
Results are presented in Table 4. Nnorepinephrine levels were
inversely associated with TSAT (b=0.124; P=0.003) and
were positively associated with sTfR levels (b=0.115;
P=0.006). On the other hand, there was no statistically
significant association of norepinephrine levels with either
ferritin or hemoglobin. Multivariate models analyzing iron
status were adjusted by factors associated with abnormal iron
status represented in Table 2 and also body mass index,
because it remained at the limit of significance in the
univariate analysis (odds ratio, 1.027 [0.997–1.057];
P=0.075).
Multivariable-Adjusted Associations Between
Serum Iron Status and Norepinephrine Levels
Figure 2 displays the adjusted marginal means of serum
norepinephrine according to different iron deficient and










Ferritin index, [IQR] 0.76 [0.54–1.14] 0.72 [0.53–1.14] 0.72 [0.55–1.06] 0.8 [0.56–1.20] 0.348*
Serum iron, mg/dL [IQR] 57 [42–79] 56 [41–77] 61 [43–84] 52 [40–74] 0.007*
Endogenous erythropoietin, U/L [IQR] 15 [9–25] 14.1 [8–22] 15 [9–25] 17 [9–26] 0.267*
Data are presented as meansSD, medians (25th–75th percentile), or numbers (with percentages), where appropriate. Anemia is defined as hemoglobin level <12 g/dL in women and
<13 g/dL in men. Impaired iron transport is defined as TSAT <20%; impaired iron storage is defined as ferritin <100 lg/L; and impaired iron status is defined as ferritin <100 lg/L or
TSAT <20%. Raised sTfR = soluble transferrin receptor >75th percentile. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index;
BP, blood pressure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resincronization therapy; ferritin index, sTfR/log10[ferritin]; HFmrEF, heart
failure with mid-range ejection fraction (defined as LVEF 40–49%); HFpEF, heart failure with preserved ejection fraction (defined as LVEF >50%); HFrEF, heart failure with reduced ejection
fraction (defined as LVEF <40%); ICD, implantable cardioverter-defibrillator; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-brain-type natriuretic peptide; NYHA, New York Heart Association functional class; sTfR, soluble transferrin receptor; TSAT, transferrin saturation; T1, first tertile; T2, second tertile; T3,
third tertile.
*P value from nonparametric tests (Kruskal–Wallis).
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Results were consistent with the previous analyses: Nore-
pinephrine levels were significantly higher in patients with
impaired iron status than in those with normal iron status
(528 [505–551] versus 482 pg/mL [448–518]; P value,
0.038); in patients with impaired iron transport than in those
with normal iron transport (537 [511–566] versus 482 pg/
mL [452–513]; P value, 0.012); and in patients with increased
iron demand defined as levels of sTfR >75th percentile than in
those with normal iron demand (590 [540–646] versus
518 pg/mL [492–545]; P value, 0.014).
Also, there was a progressive increase in adjusted
norepinephrine marginal means in each consecutive sTfR
quartile. In contrast, adjusted norepinephrine levels were not
significantly different according to iron storage or anemia
status (all P>0.05).
Discussion
In a sample of 742 patients with CHF, raised norepinephrine
levels were associated with impaired iron status and,
particularly, with those biomarkers that suggest impaired
Figure 1. Unadjusted associations between norepinephrine
levels (log-transformed) and levels of serum biomarkers of iron
status. The associations were calculated using generalized
additive models (GAM). Association between log norepinephrine
serum levels and log TSAT (A), log NE serum levels and log sTfR
(B), and log norepinephrine serum levels and log ferritin (C). sTfR
indicates soluble transferrin receptor; TSAT, transferrin
saturation.
Table 2. Baseline Variables With Statistically Significant
Associations With Abnormal Iron Status in Bivariate Logistic
Regression Analyses
OR (95% CI) P Value
Age (per y) 1.026 (1.012–1.040) <0.001
Sex (male vs female) 1.654 (1.198–2.284) 0.002
DM (yes vs no) 1.533 (1.116–2.105) 0.008
SBP (per mm Hg) 1.008 (1.001–1.015) 0.021
LVEF (per 1%) 1.012 (1.003–1.021) 0.012
eGFR (per 1 mL/min/1.73 cm2) 0.991 (0.985–0.997) 0.006
logNT-proBNP (per 1 pg/mL) 1.553 (1.187–2.031) 0.001
Albumin (per 1 g/dL) 0.555 (0.388–0.792) 0.001
hs-CRP (per 1 mg/L) 1.183 (1.076–1.301) 0.001
Hemoglobin (per 1 g/dL) 0.727 (0.662–0.797) <0.001
Anemia (yes vs no) 2.707 (1.912–3.833) <0.001
ACEI (yes vs no) 0.486 (0.345–0.684) <0.001
ARB (yes vs no) 2.066 (1.322–3.229) 0.001
HDZ+NTG (yes vs no) 2.060 (1.335–3.181) 0.001
MRA (yes vs no) 0.718 (0.524–0.984) 0.039
Na <135 (yes vs no) 2.844 (1.091–7.411) 0.032
NYHA III to IV (yes vs no) 1.438 (1.045–1.977) 0.026
logNE (per log 1 pg/mL) 2.026 (1.091–3.762) 0.025
NE>p90 (yes vs no) 2.737 (1.414–5.299) 0.003
Anemia is defined as hemoglobin level <12 g/dL in women and <13 g/dL in men.
Impaired iron status is defined as ferritin <100 lg/L or TSAT <20%. ACEI indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DM,
diabetes mellitus; eGFR, estimated glomerular filtration rate; HDZ+NTG, hydralazine and
nitrates; hs-CRP, high-sensitivity C-reactive protein; logBNP, log N-terminal pro-brain-
type natriuretic peptide; logNE, log norepinephrine concentration; LVEF, left ventricular
ejection fraction; MRA, mineralcorticoid receptor antagonists; NE>p90, norepinephrine
serum concentration >90th percentile (1050 pg/mL); NYHA, New York Heart
Association functional class; SBP, systolic blood pressure.
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iron transport (TSAT <20%) and increased iron demand (raised
levels of sTfR). This is particularly important given that these 2
iron-deficient states have been shown to strongly correlate
with worse clinical profile and prognosis in patients with
CHF.20 Given the proven role of neurohormonal activation
and, particularly, sympathetic activation in the pathophysio-
logical cascade leading to, and promoting the progression of,
CHF, the new data emerging from our study are particularly
relevant given that they may support the hypothesis that iron
deficiency might not just be a comorbidity, but could also be a
key element in the pathophysiological sequence leading to,
and promoting the progression of, CHF. To the best of our
knowledge, this is the first clinical study suggesting a
potential interplay between norepinephrine levels as a
surrogate of activation of the sympathetic system and the
frequent dysregulation of iron metabolism observed in
patients with CHF.
It is well known that iron deficiency is common in patients
with CHF, and it is associated with worse quality of life,
functional capacity, and prognosis.1–6 The negative impact of
iron deficiency may not only be explained by the role of iron in
erythropoiesis, but may also be driven by the effects of iron in
cardiomyocyte function and, particularly, in mitochondrial
respiration. These effects have been confirmed in cellular
models where iron deficiency in the cardiomyocyte leads to
mitochondrial dysfunction, hypertrophy, impaired cardiomy-
ocite contractility, and ventricular dysfunction21–28 and where
restoration of intracellular iron levels reversed these
effects.27–29 Haddad et al showed, in an animal model of
cardiac iron deficiency, that the myocardium of these animals
showed impaired mitochondrial respiration at the cardiomy-
ocyte level and a blunted response in ventricular contractility
after administration of dobutamine. Interestingly, these abnor-
malities were reversed after administration of intravenous
iron.27 At a clinical level, cohort studies conducted in healthy
individuals in whom impaired iron status was associated with
higher risk of developing heart failure (HF) over time may give
further support to the hypothesis that iron may be involved in
the pathophysiological sequence leading to HF.30
Disturbances in energy metabolism at the cellular level and
impairment of the contractile function of cardiomyocytes and
skeletal muscle cells as a result of iron deficiency may affect
patients across all LVEF categories and may promote disease
progression in all of them.
A previous study of our group showed that the particular
iron states that are associated with a worse clinical profile
and prognosis are those that entail abnormalities in the
transport of iron or an increased demand of iron at the cellular
level. However, in the above-mentioned study, isolated
abnormalities at the storage level, represented by normal
TSAT and low ferritin, were associated with a clinical profile
and prognosis undistinguishable from patients with CHF and
normal iron status.20 Interestingly, in the present study, a
raised sympathetic nervous system (SNS) activity, repre-
sented by raised norepinephrine levels, was particularly
associated with biomarkers suggesting abnormalities in iron
Table 3. Bi- and Multivariate-Adjusted Associations Between High Norepinephrine Levels (>90th Percentile) and Impaired Iron
Status States
Raised Norepinephrine
Unadjusted Models Adjusted Models
OR 95% CI P Value OR 95% CI P Value
Impaired iron status 2.589 1.334 to 5.025 0.005 2.206 1.105 to 4.405 0.025
Impaired iron transport 2.824 1.566 to 5.095 0.001 2.276 1.192 to 4.346 0.013
Impaired iron storage 1.083 0.656 to 1.787 0.756 1.253 0.728 to 2.155 0.415
Increased iron demand 2.376 1.339 to 4.215 0.003 2.229 1.239 to 4.009 0.007
Anemia 1.606 0.983 to 2.622 0.058 1.149 0.657 to 2.009 0.627
Anemia is defined as hemoglobin level <12 g/dL in women and <13 g/dL in men. Impaired iron transport is defined as TSAT <20%; impaired iron storage is defined as ferritin <100 lg/L;
impaired iron status is defined as ferritin <100 lg/L or TSAT <20%; and increased iron demand is defined as soluble transferrin receptor >75th percentile. Raised norepinephrine =
norepinephrine serum concentration >90th percentile. OR indicates odds ratio.
Table 4. Bivariate and Multivariate-Adjusted Associations
Between Increasing Levels of NE and Levels of Iron Status
Biomarkers (All Log-Transformed)
log NE
Unadjusted Models Adjusted Models
R2 Β P Value R2 Β P Value
log iron 0.014 0.120 0.001 0.379 0.071 0.019
log ferritin 0.000 0.017 0.642 0.084 0.024 0.503
log TSAT 0.022 0.148 <0.001 0.255 0.124 0.003
log sTfR 0.014 0.116 0.007 0.076 0.115 0.006
log Hb 0.002 0.039 0.288 0.245 0.005 0.878
logHb indicates log haemoglobin; log NE, log norepinephrine; logsTfR, log soluble
transferrin receptor; logTSAT, log transferrin saturation.
DOI: 10.1161/JAHA.118.010887 Journal of the American Heart Association 7















transport and increased iron demand at the cellular level. This
association was independent of relevant factors such as body
mass index and inflammatory status.31,32
It has been suggested that systemic iron depletion may
precede iron deficiency at the myocardial level. Occult blood
loss attributed to use of antiplatelet agents or anticoagulants,
poor intake of iron in diet, and reduced intestinal absorption
attributed to inflammation, among other factors, have been
suggested as potential causes of systemic iron deficiency in
these patients.33 However, despite these assumptions, the
exact mechanisms by which CHF patients develop iron
deficiency at a systemic and myocardial level are still
unknown. In consequence, it is important to investigate
alternative mechanisms that may lead to iron deficiency at the
cardiomyocyte level on top of systemic iron deficiency. From
this point of view, the interplay between iron metabolism
disturbances and neurohormonal activation represented by
raised levels of norepinephrine in patients with CHF observed
in our study needs to be taken into account. Activation of the
SNS, which involves an elevation of serum norepinephrine
levels, has long-term deleterious effects on CHF and is one of
the main therapeutic targets in HF.7,8 From our data, we
suggest that the SNS could play a role in dysregulation of iron
homeostasis in patients with CHF. Our observations are
consistent with those from basic science models. Exposure of
adult cardiomyocyte to norepinephrine leads to a downreg-
ulation of type 1 transferrin receptor expression.16 These
molecular changes may lead to intracellular iron depletion. In
the same study, exposure of cardiomyocytes to the beta
agonist, isoprenaline, also entails downregulation of type 1
transferrin receptor.16 In another study, Melenovsky et al
analyzed cardiomyocytes from hearts of patients transplanted
because of advanced HF.29 Compared with controls, car-
diomyocytes of patients with HF showed reduced levels of
intracellular iron. In this study, iron deficiency at the
myocardial level was associated with a lower treatment rate
with beta-blockers. This association may give further support
to the hypothesis that the modulation of the neurohormonal
drive of the sympathetic system by using beta-blockers may
interplay with the development of iron abnormalities at the
myocardial level in patients with HF.
Taking all into account, we may hypothesize that iron
deficiency might be a relevant factor involved in the complex
pathophysiological cascade of HF given that it may be
involved in the initiation and progression of the functional
abnormalities observed in these patients leading to clinical
events and functional impairments. According to this hypoth-
esis, iron deficiency may be not just an “unpleasant innocent
bystander,” but a key factor actively involved in the mecha-
nisms involved in onset and progression of CHF.
Study Limitations
Our study has several limitations that must be discussed. First
of all, in this study, we conducted a cross-sectional analysis;
therefore, causality may not be inferred. The deleterious
influence between the 2 terms of the equation may be
bidirectional. Raised norepinephrine levels as an expression
of sympathetic activation may promote iron depletion at a
cellular level, particularly in patients with systemic iron
deficiency; on the other hand, it is also possible that systemic
iron deficiency may lead to a greater impairment in cardiomy-
ocyte function and mitochondrial function that would lead to
more-pronounced oxidative stress, cardiomyocyte death, pump
failure, and an enhanced (compensatory) neurohormonal
activation represented by raised norepinephrine levels. This
will promote HF progression and clinical adverse events.
Second, because this was a single-center study, our
findings may not be representative of other CHF patient
populations. Third, SNS activity is a complex concept that
entails several biomarkers and measures. Using nore-
pinephrine levels as a marker of sympathetic activation may
Figure 2. Predicted adjusted marginal means of serum norepinephrine levels by iron status categories. Norepinephrine adjusted marginal
means calculated with general linear models according to (A) iron status, (B) iron transport, and (C) iron demand: sTfR classified in quartiles
(Q1 ≤1.21 mg/L; Q2 1.22–1.60 mg/L; Q3 1.61–2.24 mg/L; Q4 ≥2.25 mg/L). Impaired iron status was defined as TSAT <20% or ferritin
<100 ng/mL. Impaired iron transport was defined as TSAT <20%. sTfR indicates soluble transferrin receptor; TSAT, transferrin saturation.
DOI: 10.1161/JAHA.118.010887 Journal of the American Heart Association 8















be seen as a simplification of the SNS. Third, SNS activity is a
complex concept that may be defined by combined informa-
tion obtained from several biomarkers and functional mea-
sures. According to this, estimation of SNS activity based on
norepinephrine levels alone may be considered an oversim-
plification. Nevertheless, this parameter was used as a
surrogate of the SNS when the neurohormonal hypothesis
was developed and guided the development of key therapeu-
tic strategies for treatment of CHF patients Although sample
processing and the laboratory method of analysis of nore-
pinephrine are complex and may be seen as limitations of our
study, we want to highlight that the procedures followed for
obtaining and processing the samples and for measuring
norepinephrine levels were accurate and based on standard-
ized laboratory methods.
And, fourth, we used biomarkers that indirectly estimate
the true iron status; however, these biomarkers are those
used in daily clinical practice.29,34
Conclusions
In patients with CHF, an increased sympathetic activation
estimated with raised norepinephrine levels is associated with
impaired iron status. Specifically, we observed robust, inde-
pendent associations between norepinephrine levels and
dysregulation of biomarkers suggesting impaired iron trans-
port (low TSAT) and increased iron demand (raised sTfR),
whereas no associations were identified with iron storage
(ferritin) or presence of anemia. Longitudinal studies are
needed to better understand the directionality and potential
causal relationship underlying the observed associations.
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